Alimera Sciences Année d'introduction en bourse
Quel est le Année d'introduction en bourse de Alimera Sciences?
Le Année d'introduction en bourse de Alimera Sciences Inc. est 2010
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur NASDAQ par rapport à Alimera Sciences
Que fait Alimera Sciences?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Entreprises avec année d'introduction en bourse similaire à Alimera Sciences
- Chigo a Année d'introduction en bourse de 2009
- Jade Road Investments a Année d'introduction en bourse de 2009
- Equity Metals a Année d'introduction en bourse de 2009
- Kerr Mines a Année d'introduction en bourse de 2009
- China e-Wallet Payment a Année d'introduction en bourse de 2009
- SQS India BFSI a Année d'introduction en bourse de 2009
- Alimera Sciences a Année d'introduction en bourse de 2010
- Broken Hill Prospecting a Année d'introduction en bourse de 2011
- Apollo Global Management Inc a Année d'introduction en bourse de 2011
- Hipo Resources a Année d'introduction en bourse de 2011
- Cogra 48 SA a Année d'introduction en bourse de 2011
- New Mountain Finance Corp a Année d'introduction en bourse de 2011
- Marfrig Global Foods SA a Année d'introduction en bourse de 2011